BioLife Solutions, Inc. (NASDAQ:BLFS) EVP Aby J. Mathew Sells 517 Shares of Stock

BioLife Solutions, Inc. (NASDAQ:BLFSGet Free Report) EVP Aby J. Mathew sold 517 shares of the business’s stock in a transaction on Wednesday, May 29th. The shares were sold at an average price of $21.78, for a total transaction of $11,260.26. Following the transaction, the executive vice president now owns 318,483 shares in the company, valued at approximately $6,936,559.74. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

BioLife Solutions Stock Down 1.2 %

Shares of BLFS opened at $21.48 on Friday. BioLife Solutions, Inc. has a 12-month low of $8.92 and a 12-month high of $24.50. The company has a debt-to-equity ratio of 0.05, a current ratio of 2.89 and a quick ratio of 1.77. The firm has a fifty day moving average price of $18.71 and a 200-day moving average price of $17.01.

BioLife Solutions (NASDAQ:BLFSGet Free Report) last released its quarterly earnings data on Thursday, May 9th. The medical equipment provider reported ($0.19) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.06. BioLife Solutions had a negative net margin of 45.84% and a negative return on equity of 12.89%. The company had revenue of $31.73 million during the quarter, compared to analyst estimates of $29.30 million. During the same period in the prior year, the firm earned ($0.27) earnings per share. On average, equities analysts expect that BioLife Solutions, Inc. will post -0.5 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on BLFS shares. Benchmark upgraded shares of BioLife Solutions from a “neutral” rating to a “buy” rating and set a $25.00 price objective on the stock in a research report on Monday, May 13th. Jefferies Financial Group initiated coverage on shares of BioLife Solutions in a research note on Thursday, April 4th. They set a “buy” rating and a $22.00 target price for the company. Finally, StockNews.com raised shares of BioLife Solutions to a “sell” rating in a research note on Friday, May 10th. One analyst has rated the stock with a sell rating and five have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $23.67.

Read Our Latest Analysis on BLFS

Institutional Trading of BioLife Solutions

A number of hedge funds have recently added to or reduced their stakes in BLFS. Allspring Global Investments Holdings LLC lifted its stake in BioLife Solutions by 88.4% in the third quarter. Allspring Global Investments Holdings LLC now owns 11,346 shares of the medical equipment provider’s stock worth $157,000 after acquiring an additional 5,324 shares during the period. Illinois Municipal Retirement Fund purchased a new stake in BioLife Solutions in the third quarter worth about $270,000. Barclays PLC lifted its position in shares of BioLife Solutions by 205.3% during the third quarter. Barclays PLC now owns 56,968 shares of the medical equipment provider’s stock valued at $787,000 after buying an additional 38,311 shares during the last quarter. New York State Common Retirement Fund lifted its position in shares of BioLife Solutions by 11.9% during the third quarter. New York State Common Retirement Fund now owns 419,618 shares of the medical equipment provider’s stock valued at $5,795,000 after buying an additional 44,714 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its position in shares of BioLife Solutions by 6.3% during the third quarter. Charles Schwab Investment Management Inc. now owns 281,998 shares of the medical equipment provider’s stock valued at $3,894,000 after buying an additional 16,754 shares during the last quarter. 93.24% of the stock is owned by hedge funds and other institutional investors.

About BioLife Solutions

(Get Free Report)

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.

Featured Stories

Insider Buying and Selling by Quarter for BioLife Solutions (NASDAQ:BLFS)

Receive News & Ratings for BioLife Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLife Solutions and related companies with MarketBeat.com's FREE daily email newsletter.